have spo2 ≤ 93% on room air at sea level or pao2/fio2 < 300, respiratory rate ≥30 per minute, heart rate ≥125 per minute estimated glomerular filtration rate (egfr) < 30 ml/min serum total bilirubin > 1.5 x uln (upper limit of normal) and ast and alt >3x uln subjects with significant cardiovascular disease as following: i. heart failure nyha class ≥3 ii. left ventricular ejection fraction <50% iii. those with a history of cardiac arrhythmias, including long qt syndrome. has been admitted to a hospital prior to randomization, or is hospitalized (inpatient) at randomization, due to covid-19 or requires treatment with supplemental oxygen. have known allergies to any of the components used in the formulation of the interventions. have hemodynamic instability requiring use of vasopressors within 24 hours of randomization. suspected or proven serious, active bacterial, fungal, viral, or other infection (except covid-19) that in the opinion of the investigator could constitute a risk when taking intervention (i.e. known history of human immunodeficiency virus [hiv]). have any co-morbidity requiring surgery within <7 days, or that is considered life-threatening within 30 days. have any serious concomitant systemic disease, condition, or disorder that, in the opinion of the investigator, should preclude participation in this study.

have spo2 ≤ 93% on room air at sea level or pao2/fio2 < 300, respiratory rate ≥30 per minute, heart rate ≥125 per minute estimated glomerular filtration rate (egfr) < 30 ml/min serum total bilirubin > 1.5 x uln (upper limit of normal) and ast and alt >3x uln subjects with significant cardiovascular disease as following: i. heart failure nyha class ≥3 ii. left ventricular ejection fraction <50% iii. those with a history of cardiac arrhythmias, including long qt syndrome. has been admitted to a hospital prior to randomization, or is hospitalized (inpatient) at randomization, due to covid-19 or requires treatment with supplemental oxygen. have known allergies to any of the components used in the formulation of the interventions. have hemodynamic instability requiring use of vasopressors within 24 hours of randomization. suspected or proven serious, active bacterial, fungal, viral, or other infection (except covid-19) that in the opinion of the investigator could constitute a risk when taking intervention (i.e. known history of human immunodeficiency virus [hiv]). have any co-morbidity requiring surgery within <7 days, or that is considered life-threatening within 30 days. have any serious concomitant systemic disease, condition, or disorder that, in the opinion of the investigator, should preclude participation in this study.

1. have spo2 ≤ 93% on room air at sea level or pao2/fio2 < 300, respiratory rate ≥30 per minute, heart rate ≥125 per minute 2. estimated glomerular filtration rate (egfr) < 30 ml/min 3. serum total bilirubin > 1.5 x uln (upper limit of normal) and ast and alt >3x uln 4. subjects with significant cardiovascular disease as following: i. heart failure nyha class ≥3 ii. left ventricular ejection fraction <50% iii. those with a history of cardiac arrhythmias, including long qt syndrome. 5. has been admitted to a hospital prior to randomization, or is hospitalized (inpatient) at randomization, due to covid-19 or requires treatment with supplemental oxygen. 6. have known allergies to any of the components used in the formulation of the interventions. 7. have hemodynamic instability requiring use of vasopressors within 24 hours of randomization. 8. suspected or proven serious, active bacterial, fungal, viral, or other infection (except covid-19) that in the opinion of the investigator could constitute a risk when taking intervention (i.e. known history of human immunodeficiency virus [hiv]). 9. have any co-morbidity requiring surgery within <7 days, or that is considered life-threatening within 30 days. 10. have any serious concomitant systemic disease, condition, or disorder that, in the opinion of the investigator, should preclude participation in this study.

1. have spo2 ≤ 93% on room air at sea level or pao2/fio2 < 300, respiratory rate ≥30 per minute, heart rate ≥125 per minute 2. estimated glomerular filtration rate (egfr) < 30 ml/min 3. serum total bilirubin > 1.5 x uln (upper limit of normal) and ast and alt >3x uln 4. subjects with significant cardiovascular disease as following: i. heart failure nyha class ≥3 ii. left ventricular ejection fraction <50% iii. those with a history of cardiac arrhythmias, including long qt syndrome. 5. has been admitted to a hospital prior to randomization, or is hospitalized (inpatient) at randomization, due to covid-19 or requires treatment with supplemental oxygen. 6. have known allergies to any of the components used in the formulation of the interventions. 7. have hemodynamic instability requiring use of vasopressors within 24 hours of randomization. 8. suspected or proven serious, active bacterial, fungal, viral, or other infection (except covid-19) that in the opinion of the investigator could constitute a risk when taking intervention (i.e. known history of human immunodeficiency virus [hiv]). 9. have any co-morbidity requiring surgery within <7 days, or that is considered life-threatening within 30 days. 10. have any serious concomitant systemic disease, condition, or disorder that, in the opinion of the investigator, should preclude participation in this study.